Philips Respironics introduces Sleepwave first non-pharmacologic insomnia therapy device for release in Australia


July 1, 2010

Sydney, Australia – Philips Respironics, a global leader in sleep therapy innovations has announced a limited release in Australia of SleepWave, the first insomnia therapy device proven to help induce sleep. SleepWave is a unique, non-pharmacologic treatment that may be useful for patients with chronic or acute insomnia. The device which is approximately the size of an MP3 player is designed to non-invasively stimulate the vestibular nerve by mimicking a swaying sensation that could lead to earlier onset and relaxing sleep. 


“Insomnia is a growing problem globally with over 60% of people reporting difficulty going to sleep and an increasing rate of prescriptions being written for sleep conditions,” said Dr. David White, Chief Medical Officer, Philips Respironics. “In Australia the numbers are consistent with an alarming 10% of adults taking prescription medications to help induce sleep .” 


SleepWave is an innovative device proven to help induce sleep, and an ideal alternative to prescription and over-the-counter sleep aids . Australian insomnia sufferers will be the first to access this exciting new therapy.


Philips Respironics has been researching a non-pharmacologic option for insomnia sufferers since the late 1990s.  Combining the evidence suggesting that the movement created when rocking a baby or riding in train carriage were conducive to sleeping, researchers designed SleepWave to create a similar effect from the comfort of a bed. 


SleepWave is an easy to use alternative to prescription and over the counter sleep aids, which can be used every night or when needed. Once placed behind the ear and activated SleepWave will operate for one hour, inducing a gentle, swaying sensation.


In 2009, Philips conducted its first Sleep Survey in order to obtain an indication of people’s sleeping habits and their awareness of the effects of the impact of sleep on health and quality of life.  According to the survey over 60% of respondents admit to a suffering from a lack of sleep, which can result in lessened concentration, patience, enthusiasm and impaired judgment which affect both their personal and work life.


1.Healthy Sleep. Pfizer Australia Health Report Issue 35. March, 2007
 2. Zammit G, Lankford D, Rosenberg R, et al.  The effect of Vestibular System stimulation on transient insomnia induced by a five-hour sleep phase advance. 2009. Data on File, Philips Respironics

For further information, please contact:

Sarah Campbell
Philips Corporate Communications
Tel: +61 421 612 994

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified Health and Well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity”. Headquartered in the Netherlands, Philips employs approximately 116,000 employees in more than 60 countries worldwide. With sales of EUR 23 billion in 2009, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at